1. Chinese Weight-Loss Market Underperforms

• Novo Nordisk's CEO highlighted that the Chinese weight-loss drug market is lagging, primarily due to limited existing options.
• A key patent for Wegovy is set to expire next year, which could increase competition in the market.

2. U.S. Pricing Deal Impacts 2026 Growth

• Novo Nordisk’s pricing agreement with the U.S. is expected to slow growth in 2026.
• However, the deal is projected to boost sales from 2027 onward.
• Following this announcement, shares fell by 2.6%.

3. Board Overhaul Planned

• Novo Nordisk will elect a new chairman and six new board members.
• Five current directors will remain on the board.
• Mikael Dolsten has withdrawn, with a new member expected next year.